AerCap
AER NYSE Trading Companies & Distributors Financials FY2016βFY2025
AerCap's revenue rose 6.5% to $8.5 billion in fiscal 2025. Its net margin was 44.0%, up from 26.2% a year earlier. It paid out $192 million in dividends and buybacks. The diluted share count fell 9.4%.
Last close Β· Oct 23, 2026
$145.92
οΏ½οΏ½About these figures. AerCap is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.
What AerCap does
No business description yet.
- Legal name
- AerCap Holdings N.V.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- β
- Accession Β· CIK
- 0001628280-26-007513
0001378789
Revenue and margins
AerCap had $8.5B of revenue in fiscal 2025, up 6.5% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 16.2% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
AerCap returned $192M to shareholders in fiscal 2025. The diluted share count fell 9.5%.
Balance sheet
Cash, debt and the ratios that show how comfortably AerCap can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.7B | $1.6B | $1.6B | $1.2B | $1.4B |
| Debt incl. finance leases | $50.3B | $46.7B | $46.6B | $45.4B | $43.7B |
| Net debt / EBITDA | 11.8x | 15.1x | 6.0x | 6.7x | 4.9x |
| Debt / equity | 3.0x | 2.9x | 2.8x | 2.6x | 2.4x |
| Interest coverage | 1.9x | 0.4x | 2.8x | 2.3x | 3.1x |
| Total assets | $74.6B | $69.7B | $71.3B | $71.4B | $71.7B |
| Total liabilities | $57.9B | $53.5B | $54.7B | $54.3B | $53.3B |
| Shareholders' equity | $16.6B | $16.1B | $16.6B | $17.2B | $18.3B |
| Net debt (β = net cash) | $48.6B | $45.1B | $45.0B | $44.2B | $42.3B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 9 | β / 9 | β / 9 |
| Accruals ratio | β3.0% | β4.7% | β2.3% |
| Altman Z'' | β | β | β |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| AerCap AER | $25.7B | 6.5% | β | β | 8.5% | β | β | |
| Fastenal FAST | $59.7B | 8.7% | 20.2% | 12.8% | 34.3% | 42.2x | 7 | Compare β |
| Core & Main CNM | $8.1B | 2.8% | 9.4% | 7.9% | 13.7% | 17.3x | 7 | Compare β |
| Watsco WSO | $12.3B | β5.0% | 10.0% | 7.4% | 20.1% | 27.8x | 6 | Compare β |
| Applied Industrial Technologies AIT | $12.0B | 8.8% | 11.1% | 9.3% | 20.8% | 29.0x | 7 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.2B | $5.0B | $4.8B | $4.9B | $4.5B | $5.2B | $7.0B | $7.6B | $8.0B | $8.5B |
| Interest expense | $1.1B | $1.1B | $1.2B | $1.3B | $1.2B | $1.2B | $1.6B | $1.8B | $1.8B | $1.9B |
| Pretax income | $1.2B | $1.2B | $1.2B | $1.3B | β$315M | $1.1B | β$1.0B | $3.3B | $2.3B | $4.1B |
| Income tax | $174M | $165M | $144M | $168M | β$17.2M | $163M | β$164M | $291M | $324M | $555M |
| Net income | $1.0B | $1.1B | $1.0B | $1.1B | β$299M | $1.0B | β$726M | $3.1B | $2.1B | $3.8B |
| Diluted EPS | $5.52 | $6.43 | $6.83 | $8.43 | β$2.34 | $6.71 | β$3.02 | $13.78 | $10.79 | $21.30 |
| Diluted shares | 0.19B | 0.17B | 0.15B | 0.14B | 0.13B | 0.15B | 0.24B | 0.23B | 0.19B | 0.18B |
| Cash flow | ||||||||||
| Cash from operations | $3.4B | $3.1B | $2.8B | $3.1B | $2.1B | $3.7B | $5.2B | $5.3B | $5.4B | $5.4B |
| Depreciation and amortization | $1.8B | $1.7B | $1.7B | $1.7B | $1.6B | $1.7B | $2.4B | $2.5B | $2.6B | $2.6B |
| Stock-based compensation | $103M | $108M | $95.2M | $69.4M | $69.2M | $96.1M | $103M | $97.1M | $111M | $166M |
| Acquisitions | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $22.5B | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $140M | $192M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $140M | $192M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.0B | $1.7B | $1.2B | $1.1B | $1.2B | $1.7B | $1.6B | $1.6B | $1.2B | $1.4B |
| Total debt | $27.7B | $28.4B | $29.5B | $29.5B | $28.7B | $50.2B | $46.5B | $46.5B | $45.3B | $43.6B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $136M | $111M | $141M | $137M | $140M | $136M | $126M |
| Inventory | $52.7M | $39.0M | $31.0M | $3.2M | $0.0M | $48.6M | $55.9M | $85.7M | $90.9M | $112M |
| Property and equipment, net | β | β | $35.1B | $35.9B | $35.2B | $57.8B | $55.2B | $57.1B | $58.6B | $57.8B |
| Total assets | $41.6B | $42.0B | $43.2B | $43.7B | $42.0B | $74.6B | $69.7B | $71.3B | $71.4B | $71.7B |
| Total liabilities | $33.0B | $33.4B | $34.3B | $34.4B | $33.1B | $57.9B | $53.5B | $54.7B | $54.3B | $53.3B |
| Shareholders' equity | $8.5B | $8.6B | $8.8B | $9.3B | $8.9B | $16.6B | $16.1B | $16.6B | $17.2B | $18.3B |
| Margins | ||||||||||
| EBITDA margin | 79.3% | 80.9% | 83.4% | 87.3% | 57.4% | 78.8% | 42.5% | 99.7% | 83.2% | 101.6% |
| Net margin | 20.3% | 21.4% | 21.2% | 23.2% | β6.6% | 19.2% | β10.4% | 41.4% | 26.2% | 44.0% |
| Returns | ||||||||||
| Return on capital | 5.6% | 5.8% | 5.6% | 6.1% | 2.0% | 4.0% | 0.7% | 7.5% | 5.7% | 8.5% |
| Return on equity | 12.4% | 12.6% | 11.7% | 12.6% | β3.3% | 7.9% | β4.4% | 19.2% | 12.4% | 21.1% |
| Return on assets | 2.5% | 2.6% | 2.4% | 2.6% | β0.7% | 1.7% | β1.0% | 4.5% | 2.9% | 5.2% |
| Growth | ||||||||||
| Revenue growth | β2.6% | β2.2% | β4.7% | 2.9% | β9.0% | 16.3% | 34.3% | 8.1% | 5.5% | 6.5% |
| Net income growth | β11.2% | 2.8% | β5.6% | 12.8% | β126.1% | β | β172.6% | β | β33.1% | 78.7% |
| EPS growth | β3.5% | 16.5% | 6.2% | 23.4% | β127.8% | β | β145.0% | β | β21.7% | 97.4% |
| Share count change | β8.0% | β11.8% | β11.1% | β8.6% | β6.0% | 16.6% | 61.4% | β5.3% | β14.6% | β9.5% |
| Financial health | ||||||||||
| Net debt / EBITDA | 6.3x | 6.6x | 7.1x | 6.6x | 10.7x | 11.8x | 15.1x | 6.0x | 6.7x | 4.9x |
| Debt / equity | 3.3x | 3.3x | 3.3x | 3.2x | 3.3x | 3.0x | 2.9x | 2.8x | 2.6x | 2.4x |
| Interest coverage | 2.1x | 2.1x | 2.0x | 2.0x | 0.8x | 1.9x | 0.4x | 2.8x | 2.3x | 3.1x |
| Capital allocation | ||||||||||
| Stock comp / revenue | 2.0% | 2.1% | 2.0% | 1.4% | 1.5% | 1.8% | 1.5% | 1.3% | 1.4% | 2.0% |
| Quality scores | ||||||||||
| Accruals ratio | β5.5% | β4.9% | β4.3% | β4.5% | β5.7% | β4.6% | β8.2% | β3.0% | β4.7% | β2.3% |
Source: SEC EDGAR XBRL filings (CIK 0001378789). Data updated October 23, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.